Establishment Labs (NASDAQ:ESTA) Shares Up 5.4% – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares shot up 5.4% during mid-day trading on Wednesday . The stock traded as high as $29.51 and last traded at $28.78. 96,890 shares were traded during mid-day trading, a decline of 78% from the average session volume of 434,704 shares. The stock had previously closed at $27.31.

Analyst Upgrades and Downgrades

Separately, Stephens restated an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

Establishment Labs Trading Up 0.7 %

The business’s fifty day moving average is $36.45 and its two-hundred day moving average is $40.18. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The firm has a market cap of $875.19 million, a price-to-earnings ratio of -11.76 and a beta of 0.77.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Establishment Labs by 89.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock worth $1,789,000 after buying an additional 19,531 shares during the last quarter. Verition Fund Management LLC grew its holdings in Establishment Labs by 22.8% during the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after acquiring an additional 1,746 shares during the period. HighTower Advisors LLC raised its position in shares of Establishment Labs by 32.5% during the 3rd quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock valued at $446,000 after acquiring an additional 2,529 shares during the last quarter. Barclays PLC raised its position in shares of Establishment Labs by 9,643.3% during the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock valued at $1,362,000 after acquiring an additional 31,148 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its stake in shares of Establishment Labs by 30.5% in the 3rd quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock valued at $519,000 after purchasing an additional 2,805 shares during the period. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.